Nivolumab plus chemo success in gastro-oesophageal cancer not enhanced with ipilimumab

External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site

Sep 21 / Springer Healthcare

Nivolumab plus chemo success in gastro-oesophageal cancer not enhanced with ipilimumab

Oncology Gastrointestinal Cancer ESMO-2021

Description

Elizabeth Smyth takes us through the CheckMate 649 trial in patients with gastric and oesophageal cancers, commenting on the findings for adding nivolumab plus ipilimumab to chemo as first-line therapy.

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.